Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article just published in the journal Cancer has reported an association between the use of androgen deprivation therapy (ADT) and risk for blood clots among men being treated for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, blood clot, hormone, risk, thromboembolism | 9 Comments »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
A newly published article in BJU International offers data from a small, randomized, pilot study of the use of metformin and lifestyle changes in the prevention of cardiovascular morbidity and androgen deprivation therapy (ADT)-related metabolic syndrome.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, exercise, metformin, outcome | Leave a Comment »
A new study just published in BJU International offers data suggesting the idea that all men found to have positive seminal vesicles (SV+) after radical prostatectomy should receive immediate adjuvant treatment with external beam radiation and androgen deprivation therapy (ADT).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation, positive, radiation therapy, seminal vesicle | 21 Comments »
Initially, androgen deprivation therapy (ADT) was conceived of and developed as long-term, palliative therapy for men with evident and commonly painful forms of metastatic prostate cancer. The primary goal was the alleviation of pain associated with metastasis, and had little or nothing to do with the patient’s long-term survival.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, internittent, therapy | 2 Comments »
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a Comment »
As we first reported in March 2010, when data were originally presented at the Genitourinary Cancers Symposium, RTOG 94-08 has shown that 4 months of androgen deprivation therapy (ADT) before and during external beam radiation therapy (EBRT) reduces the overall and the prostate cancer-specific mortality rates for men with localized prostate cancer (clinical stages T1b, [...]
Filed under: Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation, EBRT, mortality, neoadjuvant, outcome, radiation therapy, RTOG 94-08 | Leave a Comment »
White race and low bone mineral density (osteoporosis) appear to be the only two of a dozen different potential risk factors that significantly increase the likelihood of vertebral (spinal and hip) fractures among men being treated with androgen deprivation therapy (ADT) for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, fracture, risk, vertebral | 1 Comment »
So-called “hot flashes” are a common and annoying side effect of androgen deprivation therapy for many men with high-risk and advanced forms of prostate cancer. A new study has suggested that an extract of common, garden sage (Salvia officinalis) may be an effective dietary supplement that can significantly lower frequency and intensity of hot flashes.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, extract, hot flashes, sage, Salvia officinalis | 1 Comment »
GTx, Inc. has announced the initiation of a randomized Phase IIb trial of their selective estrogen receptor α agonist Capsesaris™ (previously known as GTx-758) versus leuprolide acetate (Lupron Depot®) as first-line androgen deprivation therapy for progressive and advanced forms of prostate cancer.
Filed under: Drugs in development, Management | Tagged: androgen deprivation, Capesaris, estrogen receptor agonist, GTx-758 | Leave a Comment »
Perhaps the most interesting new data from the annual meeting of the American Society of Clinical Oncology yesterday (Sunday) was a negative result from a four-arm, randomized clinical trial.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, Effexor, hot flashes, soy, venlaxafine | 3 Comments »
For men undergoing the combination of external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT), for treatment of prostate cancer there is a significant risk for gastrointestinal (GI) toxicity over time.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, ADT, androgen deprivation, EBRT, gastrointestinal, IMRT, toxicity | Leave a Comment »
A new article offers expert perspective on the relative merits of intermittent and continuous androgen deprivation therapy (ADT) in the treatment of men with metastatic prostate cancer or recurrence of disease following first- or second-line treatment.
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation, continuous, IADT, intermittent | 1 Comment »
It will come as little surprise to regular readers of this blog that androgen deprivation therapy (ADT) is associated with effects on health-related quality of life. However, few studies have attempted to assess the impact of ADT on true “physical well-being.”
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, physical well-being, quality of life | 3 Comments »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site